We are live on
!
Find out more
enGene Therapeutics
ENGN
ENGN
37 hedge funds and large institutions have $279M invested in enGene Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.74% more ownership
Funds ownership: 79.07% → 79.81% (+0.74%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Holders
37
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$10.3M | |
| 2 | +$9.56M | |
| 3 | +$5.28M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$2.42M |
| 5 |
Morgan Stanley
New York
|
+$376K |
Top Sellers
| 1 | -$10.6M | |
| 2 | -$6.19M | |
| 3 | -$3.43M | |
| 4 |
O
OrbiMed
New York
|
-$2.47M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
-$2.05M |